pubmed.ncbi.nlm.nih.gov

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function - PubMed

Review

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function

Benedetto Vitiello. Child Adolesc Psychiatr Clin N Am. 2008 Apr.

Abstract

The effects of stimulant medications and atomoxetine on physical growth and on cardiovascular function are reviewed in light of the most recent data, with attention to clinical implications and research needs. Although these medications have a favorable benefit/risk profile and do not induce clinically significant changes in growth or cardiovascular function in the majority of cases, careful patient monitoring is needed to identify individuals at risk for negative outcomes. More research is needed to elucidate the mechanism of growth suppression to estimate better the risk for rare but life-threatening events and test the effectiveness of monitoring procedures.

PubMed Disclaimer

Cited by

Improving cognitive function in Chinese children with ADHD and/or RD through computerized working memory training.
Poon K, Ho MSH, Wang LC, Lee HM, Lau WKW, Chan WWL. Poon K, et al. BMC Psychol. 2024 Oct 18;12(1):574. doi: 10.1186/s40359-024-02065-1. BMC Psychol. 2024. PMID: 39425120 Free PMC article.
Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies.
Parens E, Johnston J. Parens E, et al. Child Adolesc Psychiatry Ment Health. 2009 Jan 19;3(1):1. doi: 10.1186/1753-2000-3-1. Child Adolesc Psychiatry Ment Health. 2009. PMID: 19152690 Free PMC article.
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C. Storebø OJ, et al. Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Cochrane Database Syst Rev. 2015. PMID: 26599576 Free PMC article. Updated. Review.
The Medical and Economic Burden of Narcolepsy: Implications for Managed Care.
Thorpy MJ, Hiller G. Thorpy MJ, et al. Am Health Drug Benefits. 2017 Jul;10(5):233-241. Am Health Drug Benefits. 2017. PMID: 28975007 Free PMC article. Review.
"A massive long way": interconnecting histories, a "special child," ADHD, and everyday family life.
Garro LC, Yarris KE. Garro LC, et al. Cult Med Psychiatry. 2009 Dec;33(4):559-607. doi: 10.1007/s11013-009-9155-1. Cult Med Psychiatry. 2009. PMID: 19787444 Free PMC article.

References

1. Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40:180–187. - PubMed
1. Wigal T, Greenhill LL, Chuang S, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1294–1303. - PubMed
1. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100:662–666. - PubMed
1. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. A randomized controlled crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62:1266–1274. - PubMed
1. Zuvekas SH, Vitiello B, Norquist NS. Recent Trends in Stimulant Medication Use among U.S. Children. Am J Psychiatry. 2006;163:579–585. - PubMed

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function - PubMed